References
- Groopman, J.E. and Itri, L.M. (1999) "Chemotherapy-induced anemia in adults: incidence and treatment", J. Natl. Cancer. Inst. 91, 1616–1634.
- Ludwig, H. and Fritz, E. (1998) "Anemia in cancer patients", Semin. Oncol. 25, 2–6.
- Winningham, Mi., Nail, L.M., Burke, MB., et al. (1994) "Fatigue and the cancer experience: the state of the know-ledge", Oncol. Nurs. Forum 21, 23–36.
- Cella, D. (1998) "Factors influencing quality of life in cancer patients: anemia and fatigue", Semin. Oncol. 25, 43–46.
- Schwartz, A.L. (1998) "The Schwartz cancer fatigue scale: testing reliability and validity", Oncol. Nurs. Forum 25,711–717.
- Caro, J.J., Salas, M., Ward, A. and Goss, G. (2001) "Anemia as an independent prognostic factor for survival in patients with cancer—A systematic, quantitative review", Cancer 91, 2214–2221.
- Littlewood, T., Bajetta, E., Nortier, J., Vercammen, E. and Rapoport, B. (2001) "Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy:results of a random-ized, double-blind, placebo-controlled trial", J. Clin. Oncol. 19, 2865–2874.
- Maraveyas, A. and Pettengell, R. (1998) "What is the role of erythropoietin in patients with solid tumours?", Ann. Oncol. 9, 239–241.
- Seidenfeld, J., Piper, M., Flamm, C., et al. (2001) "Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials", J. Natl. Cancer Inst. 93, 1204–1214.
- Rizzo, J.D., Lichtin, A.E., Woolf, S.H., et al. (2002) "Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology", Blood 100, 2303–2320.
- Abels, R.I., Larholt, KM., Krantz, K.D. and Bryant, E.C. (1991) "Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer", In: Murphy, M.J.J., ed, Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology; Proceedings of the Beijing Symposium. (Dayton, Ohio 1991) (AlphaMed Press), pp 121–141.
- Glaspy, J., Bukowski, R., Steinberg, D., et al. (1997) "Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice", J. Clin. Oncol. 15, 1218–1234.
- Glapsy, J., Jadeja, J., Justice, G., Kessler, J., Richards, D., the darbepoetin alfa 980290 Study Group, Tomita, D., Rossi, G., Colowick, A., (2002). Darbepoetin alfa administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors. Paper presented at: European Haematology Association 7th Congress; June 6–9.; Florence, Italy.
- The darbepoetin alfa 19200000174 Study Group. Glaspy, J., Jadeja, J., Justice, G., Fleishman, A., Rossi, G. and Colowick, A. (2002) Optimizing the management of anemia in patients with cancer: a randomized, active-controlled study investi-gating the dosing of darbepoetin alfa. Paper presented at: European Haematology Association 7th Congress; June 6–9; Florence, Italy.
- Ludwig, H., Sundal, E., Pecherstorfer, M., et al. (1995) "Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy", Cancer 76, 2319–2329.
- Demetri, G.D., Kris, M., Wade, J., Degos, L. and Cella, D. (1998) "Quality-of-life benefit in chemotherapy patients treated with Epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study", J. Clin. Oncol. 16, 3412–3425.
- Oken, M., Creech, R., Tormey, D., et al. (1982) "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am. J. Gin. Oncol. 5, 649–655.
- Karnofsky, D.A. and Burchenal, J.H. (1949) "The clinical evaluation of chemotherapeutic agents in cancer", In: MacLeod, C.M., ed, Evaluation of Chemotherapeutic Agents (Columbia University Press, New York), pp 191–205.